Volume 10,Issue 3
A Study on the Efficacy of Early Application of Azvudine in Viral Myocarditis under the Epidemic
Objective: To explore the efficacy of early application of Azvudine in patients with viral myocarditis during the epidemic. Methods: Sixty patients diagnosed with "infection complicated with myocarditis" in our hospital from December 2022 to December 2023 were selected and randomly divided into an intervention group and a control group, with 30 cases in each group. The intervention group was treated with 5mg of Azvudine tablets every day on the basis of conventional treatment for one consecutive week. The control group was given conventional antiviral and myocardial nutrition treatments. Compare the changes of serum myocardial injury markers (myoglobin, cardiac troponin I, CK-MB) and cardiac function indicators between the two groups of patients. Result: The improvement amplitudes of myoglobin, troponin I, CK-MB concentrations and EF (ejection fraction) in the intervention group were significantly greater than those in the control group (p<0.05). There was no significant difference in the baseline data at admission between the two groups (p>0.05), indicating that the conditions of the two groups were similar before treatment. Conclusion: Early application of Azvudine can significantly improve myocardial injury markers and cardiac function in patients with viral myocarditis, reduce the conversion rate from mild to severe cases, and shorten the length of hospital stay, which has important clinical significance.
[1]Fu P, Cao P, 2025, Risk Factors and Changes of Serum IL-6, IL-17, and TGF-β in Children With Acute Myocarditis. Clinical pediatrics, 99228251359448.
[2]Liu Y, Xu Y, Zhao R, 2025, 1,25-dihydroxyvitamin D deficiency accelerates inflammatory response by up-regulating inositol 1,4,5-triphosphate receptor in Coxsackievirus B3-induced acute myocarditis. International Immunopharmacology,163115256-115256.
[3]Hu V, Naidu I, Singh N, 2025, Cardiotoxicity Conundrum: Distinguishing Immune Checkpoint Inhibitor Myocarditis From Fluorouracil Cardiotoxicity in Concurrent Therapy. JACC. Case reports, 2025, 30(18):104002.
[4]Łukasz N, Anna D, Jakub M, 2025, From mononucleosis to heart transplantation: An uncommon course of Epstein-Barr virus-associated myocarditis. Kardiologia polska.
[5]Blagova V O, Kogan A E, Novosadov M V, 2025, Post-COVID Versus Non-COVID Myocarditis: Comparison of Morphological Activity, Toll-like Receptor Distribution and Responses to Immunosuppressive Therapy. Frontiers in bioscience (Scholar edition), 17(2):28262.
[6]Sacco A M, Gualtieri S, Verrina C M, 2025, A Narrative Overview of Fatal Myocarditis in Infant with Focus on Sudden Unexpected Death and Forensic Implications. Journal of Clinical Medicine, 14(12):4340-4340.
[7]Ren Z, Luo H, Yu Z, 2020, A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study. Adv Sci (Weinh), 7(19):e2001435.
[8]Wang R R, Yang Q H, Luo R H, 2014, Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One, 9(8):e105617.